Genprex Overview
- Year Founded
-
2009
- Status
-
Public
- Employees
-
13
- Stock Symbol
-
GNPX
- Share Price
-
$2.08
- (As of Friday Closing)
Genprex General Information
Description
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
Contact Information
Website
www.genprex.comCorporate Office
- 3300 Bee Cave Road
- Suite 650-227
- Austin, TX 78746
- United States
Corporate Office
- 3300 Bee Cave Road
- Suite 650-227
- Austin, TX 78746
- United States
Genprex Timeline
Genprex Stock Performance
As of 13-Nov-2026, Genprex’s stock price is $2.08. Its current market cap is $1.7M with 820K shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.08 | $2.21 | $1.71 - $98.78 | $1.7M | 820K | 241K | -$9.35 |
Genprex Financials Summary
As of 30-Jun-2026, Genprex has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | (12,378) | 3,198 | 5,757 | 1,951 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (16,499) | (15,489) | (21,104) | (31,061) |
| Net Income | (16,499) | (16,229) | (21,111) | (30,860) |
| Total Assets | 17,137 | 10,159 | 4,124 | 10,671 |
| Total Debt | 0 | 22 | 0 | 0 |
Genprex Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Genprex Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Genprex Comparisons
Industry
Financing
Details
Genprex Competitors (45)
One of Genprex’s 45 competitors is Sangamo Therapeutics, a Formerly VC-backed company based in Richmond, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sangamo Therapeutics | Formerly VC-backed | Richmond, CA | ||||
| Ayala Pharmaceuticals | Corporation | Wilmington, DE | ||||
| Xenetic Biosciences | Corporation | Framingham, MA | ||||
| Vertex Pharmaceuticals | Formerly VC-backed | Boston, MA | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA |
Genprex Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Genprex Patents
Genprex Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026055191-A1 | Methods and compositions for treating glioblastoma | Pending | 04-Sep-2024 | ||
| WO-2026055329-A1 | Methods and compositions for treating mesothelioma | Pending | 04-Sep-2024 | ||
| WO-2025208148-A1 | Maintenance therapy for treating cancer | Pending | 29-Mar-2024 | ||
| WO-2025171317-A1 | Methods of treating pet positive cancers | Pending | 07-Feb-2024 | ||
| WO-2025171187-A1 | Treatment of alk positive cancers | Pending | 06-Feb-2024 | A61P35/00 |
Genprex Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Genprex ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
36.57 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Genprex FAQs
-
When was Genprex founded?
Genprex was founded in 2009.
-
Where is Genprex headquartered?
Genprex is headquartered in Austin, TX.
-
What is the size of Genprex?
Genprex has 13 total employees.
-
What industry is Genprex in?
Genprex’s primary industry is Biotechnology.
-
Is Genprex a private or public company?
Genprex is a Public company.
-
What is Genprex’s stock symbol?
The ticker symbol for Genprex is GNPX.
-
What is the current stock price of Genprex?
As of 13-Nov-2026 the stock price of Genprex is $2.08.
-
What is the current market cap of Genprex?
The current market capitalization of Genprex is $1.7M.
-
Who are Genprex’s competitors?
Sangamo Therapeutics, Ayala Pharmaceuticals, Xenetic Biosciences, Vertex Pharmaceuticals, and Kite Pharma are some of the 45 competitors of Genprex.
-
What is Genprex’s annual earnings per share (EPS)?
Genprex’s EPS for 12 months was -$9.35.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
